ABCLNasdaqPharmaceutical PreparationsFiscal year ends December 31
AbCellera Biologics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$11.93+0.13 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $3.65B
- P/E (TTM)
- –
- Dividend yield
- –
AbCellera Biologics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -340.3%
- Net margin
- -248.8%
- Return on equity, FY2025
- -14.5%
Financial strength
- Current ratio
- 12.77
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 225.7%
Valuation
- P/E ratio
- –
- Price to sales
- 55.09
- Price to book
- 4.07
- Dividend yield
- –